Promising Early Results for Tisotumab Vedotin in Advanced Cervical Cancer
According to researchers, responses to tisotumab vedotin were seen in women with refractory advanced cervical cancer.
Gynecologic, Ovarian, and Cervical Cancer News
GYNECOLOGIC CANCER ADVISOR
Early Evidence of Neratinib Benefit in HER2-Positive Metastatic Cervical Cancer
Single-agent neratinib was associated with durable responses in a subcohort of women in the SUMMIT trial.
Racial Differences in Immune Escape Mechanisms of Ovarian Cancer
High expression of indoleamine 2.3-dioxygenase pathway genes correlated with the presence of immune escape mechanisms in ovarian cancers, according to researchers.
Vitiligo May Be Associated With Reduced Risk of Internal Cancer
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
Carboplatin Desensitization Associated With Improved Overall Survival in Recurrent Ovarian Cancer
The OS benefit of carboplatin desensitization was limited to the subgroup of women with recurrent ovarian cancer without deleterious germline BRCA1/2 mutations.
Maintenance Olaparib May Be More Cost-Effective Than Bevacizumab in BRCA-Mutant Ovarian Cancer
Researchers estimated cost effectiveness for first-line maintenance therapy with bevacizumab or olaparib in women with BRCA-mutant ovarian cancer.
Social and Financial Assistance Programs to Overcome Barriers for Patients With Cervical Cancer
According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.
Racial Disparities in the Use of Brachytherapy to Treat Cervical Cancer
Black women with locally advanced cervical cancer are significantly less likely to receive brachytherapy compared with non-black women with this disease.
The Relationship Between Niraparib Dose Reduction and Efficacy in Ovarian Cancer
In the QUADRA trial patients with low baseline platelet count or low body weight were more likely to experience grade 3/4 adverse events.
Experience for Women With Ovarian Cancer After Multiple Lines of PARP Inhibitor Therapy
More data are needed regarding the efficacy and safety of administering multiple lines of PARP inhibitor therapy, according to researchers.
Simultaneous Sequencing of Paired Germline and Somatic Specimens Enhanced Clinical Care in Ovarian Cancer
Simultaneous molecular characterization of paired germline and tumor specimens may gain importance as more targeted therapies become available.
ARIEL3: Rucaparib Maintenance Across Age Groups in Advanced Ovarian Cancer
Women aged 75 and older with advanced ovarian cancer enrolled in the phase 3 ARIEL3 trial were less likely to have deleterious germline or somatic BRCA mutations.
Lymphadenectomy Found Not Beneficial in Advanced Ovarian Cancer
According to researchers, the Lymphadenectomy in Ovarian Neoplasms (LION) trial was meticulously designed to eliminate many potential confounding factors.
New Epigenetic Cervical Cancer Test Outperforms Pap and HPV Testing
Epigenetic aberrations, as opposed to DNA mutations themselves, might play a more important role in the progression of many malignancies.
Lynparza OK’d as First-Line Maintenance of BRCA-Mutated Advanced Ovarian CA
Lynparza, a poly (ADP-ribose) polymerase (PARP) inhibitor is already approved to treat certain breast, epithelial ovarian, fallopian tube or primary peritoneal cancers based on an FDA-approved companion diagnostic.
Study Questions Benefits of Minimally Invasive Surgery for Early-Stage Cervical Cancer
New findings conflict with earlier retrospective studies and the general consensus supporting the use of minimally invasive surgery in early-stage cervical cancer.
Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer
Olaparib maintenance therapy after platinum chemotherapy substantially prolonged PFS compared with placebo in newly diagnosed advanced ovarian cancer.
Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer
Patients in the real world setting were initiated at a lower dose and experienced fewer side effects than trial participants.
Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.
Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian Cancer
Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.
Want to read more?
Please login or register first to view this content.
Next post in Gynecologic Cancer
